



## CHANGE IN CONSTITUTION OF THE BOARD OF DIRECTORS

*Summary: Genmab's Board of Directors to include three employee members.*

**Copenhagen, Denmark; June 2, 2010** – Genmab A/S (OMX: GEN) announced today that three Genmab employees were elected to the company's Board of Directors. In accordance with the Danish Companies Act the employees of a company are entitled to be represented on the Board of Directors if the company has employed a minimum of 35 employees on average over the past three years and the employees request such representation.

The employees of Genmab A/S chose to exercise this right and in addition, approved a voluntary arrangement, which allowed the subsidiaries of the company to also participate in the election. As a result three Genmab employees, along with three alternates, were elected by their peers to become members of the Board.

Details regarding these new board members are as follows. They will join Genmab's Board of Directors in conjunction with the June 2, 2010 Board of Directors' Meeting.

### **Daniel J. Bruno**

American, 30

Mr. Bruno joined Genmab in 2008 and is currently the Controller of Genmab's locations in the United States. Before joining Genmab he spent six years at PricewaterhouseCoopers in the Assurance and Business Advisory practice serving clients in Health Industries group, which included pharmaceutical, life science, and biotech companies. He is a Certified Public Accountant and received B.S. and M.S. degrees from Fairleigh Dickinson University.

### **Nedjad Losic**

Swedish, 41

Mr. Losic joined Genmab in 2004 and is currently Associate Director, Statistics at Genmab's location in Copenhagen. He has worked in the pharmaceutical industry since 1996. Prior to joining Genmab he held positions at Ferring Pharmaceuticals and at Spadille Sweden, where he was Managing Director. He was the responsible statistician for two successful drug applications, one in 1999 and one in 2009. He also served on the board of directors for other non-industry associations. Mr. Losic received a M.Sc. in Mathematics from the University of Lund and a diploma in Management of Medical Product Innovation from the Scandinavian International Management Institute.

### **Tom Vink, Ph.D.**

Dutch, 47

Dr. Vink joined Genmab in 2002 as Head of Molecular Biology. Currently he is leading the Cell and Molecular Science unit at Genmab's R&D facility in Utrecht. Before joining Genmab, Dr.

## CHANGE IN CONSTITUTION OF THE BOARD OF DIRECTORS

Vink worked for more than 15 years in life sciences research, specializing in molecular biology and biochemistry. Dr. Vink is the author of over 20 scientific publications and is named inventor on over 10 patents and patent applications. He received a M.S. degree in Biochemistry from Leiden University, and a Ph.D. from Utrecht University.

### About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery and development teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit [www.genmab.com](http://www.genmab.com).

*This Stock Exchange Release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section "Risk Management" in Genmab's Annual Report, which is available on [www.genmab.com](http://www.genmab.com). Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.*

Genmab<sup>®</sup>; the Y-shaped Genmab logo<sup>®</sup>; HuMax<sup>®</sup>; HuMax-CD20<sup>®</sup>; HuMax-EGFr<sup>™</sup>; HuMax-IL8<sup>™</sup>; HuMax-TAC<sup>™</sup>; HuMax-HepC<sup>™</sup>; HuMax-CD38<sup>™</sup>; HuMax-CD32b<sup>™</sup>; HuMax-TF<sup>™</sup>; HuMax-Her2<sup>™</sup>; HuMax-VEGF<sup>™</sup>; HuMax-Wnt; HuMax-cMet<sup>™</sup> and UniBody<sup>®</sup> are all trademarks of Genmab A/S. Arzerra<sup>®</sup> is a trademark of GlaxoSmithKline.

Contact: Helle Husted, Vice President, Investor Relations  
T: +45 33 44 77 30; M: +45 25 27 47 13; E: [h.husted@genmab.com](mailto:h.husted@genmab.com)

###